Please use this identifier to cite or link to this item:
Title: Comparison of oxidative stress markers in HIV-infected patients on efavirenz or atazanavir/ritonavir-based therapy.
Authors: Estrada, Vicente
Monge, Susana
Gómez-Garre, Dulcenombre
Sobrino, Paz
Berenguer, Juan
Bernardino, José Ignacio
Santos, Jesús
Moreno Zamora, Ana
Martínez, Esteban
Blanco, Jose Ramón
metadata.dc.contributor.authoraffiliation: [Estrada,V] Infectious Diseases, Hospital Clínico San Carlos, Madrid, Spain. [Monge,S; Sobrino,P] Instituto de Salud Carlos III, Centro Nacional de Epidemiología, Madrid, Spain. [Gómez-Garre,D] Vascular Biology Lab, Hospital Clinico San Carlos, Madrid, Spain. [Berenguer,J]nfectious Diseases, Hospital General Gregorio Marañón, Madrid, Spain. [Bernardino,JI] Infectious Diseases, Hospital La Paz, Madrid, Spain. [Santos,J] Infectious Diseases, Hospital Virgen de la Victoria, Málaga, Spain. [Moreno Zamora,A] Infectious Diseases, Hospital Ramón y Cajal, Madrid, Spain. [Martínez,E] Infectious Diseases, Hospital Clinic, Barcelona, Spain. [Blanco,JR] Infectious Diseases, Hospital San Pedro-CIBIR, Logroño, Spain.
Keywords: Infecciones por VIH;Estrés oxidativo;Benzoxazinas;Fármacos anti-VIH;Inhibidores de la proteasa VIH;Oligopéptidos;Estudio comparativo
metadata.dc.subject.mesh: Medical Subject Headings::Diseases::Virus Diseases::RNA Virus Infections::Retroviridae Infections::Lentivirus Infections::HIV Infections
Medical Subject Headings::Phenomena and Processes::Metabolic Phenomena::Metabolism::Oxidative Stress
Medical Subject Headings::Chemicals and Drugs::Heterocyclic Compounds::Heterocyclic Compounds, 1-Ring::Oxazines::Benzoxazines
Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents::Anti-Retroviral Agents::Anti-HIV Agents
Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protease Inhibitors
Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Oligopeptides
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Publication Characteristics::Study Characteristics::Comparative Study
Issue Date: Nov-2014
Publisher: International AIDS Society
Citation: Estrada V, Monge S, Gómez-Garre D, Sobrino P, Berenguer J, Bernardino JI, et al. Comparison of oxidative stress markers in HIV-infected patients on efavirenz or atazanavir/ritonavir-based therapy. J Int AIDS Soc. 2014; 17(4 Suppl 3):19544
Abstract: INTRODUCTION Chronic low-grade inflammation and immune activation may persist in HIV patients despite effective antiretroviral therapy (ART). These abnormalities are associated with increased oxidative stress (OS). Bilirubin (BR) may have a beneficial role in counteracting OS. Atazanavir (ATV) inhibits UGT1A1, thus increasing unconjugated BR levels, a distinctive feature of this drug. We compared changes in OS markers in HIV patients on ATV/r versus efavirenz (EFV)-based first-line therapies. MATERIALS AND METHODS Cohort of the Spanish Research Network (CoRIS) is a multicentre, open, prospective cohort of HIV-infected patients naïve to ART at entry and linked to a biobank. We identified hepatitis C virus/hepatitis B virus (HCV/HBV) negative patients who started first-line ART with either ATV/r or EFV, had a baseline biobank sample and a follow-up sample after at least nine months of ART while maintaining initial regimen and being virologically suppressed. Lipoprotein-associated Phospholipase A2 (Lp-PLA2), Myeloperoxidase (MPO) and Oxidized LDL (OxLDL) were measured in paired samples. Marker values at one year were interpolated from available data. Multiple imputations using chained equations were used to deal with missing values. Change in the OS markers was modelled using multiple linear regressions adjusting for baseline marker values and baseline confounders. Correlations between continuous variables were explored using Pearson's correlation tests. RESULTS 145 patients (97 EFV; 48 ATV/r) were studied. Mean (SD) baseline values for OS markers in EFV and ATV/r groups were: Lp-PLA2 [142.2 (72.8) and 150.1 (92.8) ng/mL], MPO [74.3 (48.2) and 93.9 (64.3) µg/L] and OxLDL [76.3 (52.3) and 82.2 (54.4) µg/L]. After adjustment for baseline variables patients on ATV/r had a significant decrease in Lp-PLA2 (estimated difference -16.3 [CI 95%: -31.4, -1.25; p=0.03]) and a significantly lower increase in OxLDL (estimated difference -21.8 [-38.0, -5.6; p<0.01] relative to those on EFV, whereas no differences in MPO were found. Adjusted changes in BR were significantly higher for the ATV/r group (estimated difference 1.33 [1.03, 1.52; p<0.01]). Changes in BR and changes in OS markers were significantly correlated. CONCLUSIONS In virologically suppressed patients on stable ART, OS was lower in ATV/r-based regimens compared to EFV. We hypothesize these changes could be in part attributable to increased BR plasma levels.
Description: Meeting abstract publicado
ISSN: 1758-2652 (Online)
Appears in Collections:01- Artículos - Hospital Virgen de la Victoria

Files in This Item:
File Description SizeFormat 
Estrada_Comparison.pdfArtículo publicado76,96 kBAdobe PDFView/Open

This item is protected by original copyright

This item is licensed under a Creative Commons License Creative Commons